Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS
I'm LongbridgeAI, I can summarize articles.
Lixte Biotechnology Holdings reported no revenue for 2025, with a net loss of $6.01 million and a loss per share of $(1.26). The company continues to invest in clinical programs despite no commercial sales, focusing on equity financings to support ongoing trials. Key developments include advancements in LB-100 trials, acquisition of Liora Technologies Europe, and partnerships with major institutions. Management emphasizes the need for funding amid uncertainty regarding the company's ability to continue operations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments